Literature DB >> 32304391

Update on in-vivo preclinical research models in adrenocortical carcinoma.

Adwitiya Kar1, Margaret E Wierman1,2, Katja Kiseljak-Vassiliades1,2.   

Abstract

PURPOSE OF REVIEW: The aim of this review is to summarize recent advances on development of in vivo preclinical models of adrenocortical carcinoma (ACC). RECENT
FINDINGS: Significant progress has been achieved in the underlying molecular mechanisms of adrenocortical tumorigenesis over the last decade, and recent comprehensive profiling analysis of ACC tumors identified several genetic and molecular drivers of this disease. Therapeutic breakthroughs, however, have been limited because of the lack of preclinical models recapitulating the molecular features and heterogeneity of the tumors. Recent publications on genetically engineered mouse models and development of patient-derived ACC xenografts in both nude mice and humanized mice now provide researchers with novel tools to explore therapeutic targets in the context of heterogeneity and tumor microenvironment in human ACC.
SUMMARY: We review current in-vivo models of ACC and discuss potential therapeutic opportunities that have emerged from these studies.

Entities:  

Mesh:

Year:  2020        PMID: 32304391      PMCID: PMC8103733          DOI: 10.1097/MED.0000000000000543

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  50 in total

1.  Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.

Authors:  Siyuan Zheng; Andrew D Cherniack; Ninad Dewal; Richard A Moffitt; Ludmila Danilova; Bradley A Murray; Antonio M Lerario; Tobias Else; Theo A Knijnenburg; Giovanni Ciriello; Seungchan Kim; Guillaume Assie; Olena Morozova; Rehan Akbani; Juliann Shih; Katherine A Hoadley; Toni K Choueiri; Jens Waldmann; Ozgur Mete; A Gordon Robertson; Hsin-Ta Wu; Benjamin J Raphael; Lina Shao; Matthew Meyerson; Michael J Demeure; Felix Beuschlein; Anthony J Gill; Stan B Sidhu; Madson Q Almeida; Maria C B V Fragoso; Leslie M Cope; Electron Kebebew; Mouhammed A Habra; Timothy G Whitsett; Kimberly J Bussey; William E Rainey; Sylvia L Asa; Jérôme Bertherat; Martin Fassnacht; David A Wheeler; Gary D Hammer; Thomas J Giordano; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

2.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

3.  Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.

Authors:  Adwitiya Kar; Yu Zhang; Betelehem W Yacob; Jordan Saeed; Kenneth D Tompkins; Stacey M Bagby; Todd M Pitts; Hilary Somerset; Stephen Leong; Margaret E Wierman; Katja Kiseljak-Vassiliades
Journal:  Endocr Relat Cancer       Date:  2019-10       Impact factor: 5.678

4.  Prevalence of adrenal incidentaloma in a contemporary computerized tomography series.

Authors:  S Bovio; A Cataldi; G Reimondo; P Sperone; S Novello; A Berruti; P Borasio; C Fava; L Dogliotti; G V Scagliotti; A Angeli; M Terzolo
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

5.  Integrated genomic characterization of adrenocortical carcinoma.

Authors:  Guillaume Assié; Eric Letouzé; Martin Fassnacht; Anne Jouinot; Windy Luscap; Olivia Barreau; Hanin Omeiri; Stéphanie Rodriguez; Karine Perlemoine; Fernande René-Corail; Nabila Elarouci; Silviu Sbiera; Matthias Kroiss; Bruno Allolio; Jens Waldmann; Marcus Quinkler; Massimo Mannelli; Franco Mantero; Thomas Papathomas; Ronald De Krijger; Antoine Tabarin; Véronique Kerlan; Eric Baudin; Frédérique Tissier; Bertrand Dousset; Lionel Groussin; Laurence Amar; Eric Clauser; Xavier Bertagna; Bruno Ragazzon; Felix Beuschlein; Rossella Libé; Aurélien de Reyniès; Jérôme Bertherat
Journal:  Nat Genet       Date:  2014-04-20       Impact factor: 38.330

6.  Adrenocortical dysplasia: a mouse model system for adrenocortical insufficiency.

Authors:  W G Beamer; H O Sweet; R T Bronson; J G Shire; D N Orth; M T Davisson
Journal:  J Endocrinol       Date:  1994-04       Impact factor: 4.286

Review 7.  Cancer immunoediting and resistance to T cell-based immunotherapy.

Authors:  Michele W L Teng; Mark J Smyth; Jake S O'Donnell
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

Review 8.  Mouse Models Recapitulating Human Adrenocortical Tumors: What Is Lacking?

Authors:  Felicia Leccia; Marie Batisse-Lignier; Isabelle Sahut-Barnola; Pierre Val; A-Marie Lefrançois-Martinez; Antoine Martinez
Journal:  Front Endocrinol (Lausanne)       Date:  2016-07-15       Impact factor: 5.555

Review 9.  Patient-Derived Xenograft Models for Endometrial Cancer Research.

Authors:  Cristian P Moiola; Carlos Lopez-Gil; Silvia Cabrera; Angel Garcia; Tom Van Nyen; Daniela Annibali; Tina Fonnes; August Vidal; Alberto Villanueva; Xavier Matias-Guiu; Camilla Krakstad; Frédéric Amant; Antonio Gil-Moreno; Eva Colas
Journal:  Int J Mol Sci       Date:  2018-08-17       Impact factor: 5.923

10.  A ZNRF3-dependent Wnt/β-catenin signaling gradient is required for adrenal homeostasis.

Authors:  Kaitlin J Basham; Stéphanie Rodriguez; Adina F Turcu; Antonio M Lerario; Catriona Y Logan; Madeline R Rysztak; Celso E Gomez-Sanchez; David T Breault; Bon-Kyoung Koo; Hans Clevers; Roeland Nusse; Pierre Val; Gary D Hammer
Journal:  Genes Dev       Date:  2019-01-28       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.